Abbott 'No-Fingerstick' CGM System For Diabetes Wins Medicare Coverage
Executive Summary
The first continuous glucose monitoring (CGM) system for diabetics that avoids fingerstick calibrations, the Abbott Freestyle Libre, now will be covered through Medicare under therapeutic CGM systems reimbursement codes.
You may also be interested in...
Lawsuit Seeks Expanded Medicare Reimbursement For CGM
A law firm has filed a class action suit against the US Department of Health and Human Services trying to force broader Medicare reimbursement of continuous glucose monitors. Currently, federal health programs will only cover specific types and uses of the diabetes treatment technology.
Q3 Earnings Spotlight: Abiomed Shines Among Cardiology Device-Makers
Reported sales and earnings from the publicly traded cardiovascular device companies show strong performance across the sector, spurred by new approvals and clinical trials, in the quarter that ended Sept. 30. Here's a recap of results from the cardio device companies that have reported so far, including Abbott, Abiomed, and Reva.
Dexcom Gains Approval For No-Calibration, 'Interoperable' CGM System
US FDA's March 27 de novo clearance of the Dexcom G6 integrated continuous glucose monitoring (iCGM) system for diabetics gives Dexcom a no-calibration offering, a first-in-class "interoperable" system and sets out a streamlined regulatory pathway for future CGM devices with similar features.